Clinical Trial Update: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 trial evaluates the combination of cirmtuzumab and ibrutinib in patients with B-cell lymphoid malignancies, including chronic lymphocyt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Cirmtuzumab (cirmtuzumab)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Oncternal Therapeutics, Inc | Conditions: B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-12